Uncovering antiobesity-related hypertension targets and mechanisms of metformin, an antidiabetic medication

References

• Bray GA, Kim KK, Wilding JPH. Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–723.
   PubMed Web of Science ®Google Scholar
• Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–298.
   PubMed Web of Science ®Google Scholar
• Chooi YC, Ding C, Magkos F. The epidemiology of obesity. Metabolism. 2019;92:6–10.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xue H, Sun M, et al. Prevention and control of obesity in China. Lancet Glob Health. 2019;7(9):1166–1167.
   PubMed Web of Science ®Google Scholar
• Oparil S, Acelajado MC, Bakris GL, et al. Hypertension. Nat Rev Dis Primers. 2018;4(1):18014.
   PubMedGoogle Scholar
• Matsumoto K, Jin Z, Homma S, et al. Association between central blood pressure and subclinical cerebrovascular disease in older adults. Hypertension. 2020;75(2):580–587.
   PubMed Web of Science ®Google Scholar
• Ventura HO, Lavie CJ. Hypertension: management and measurements. Curr Opin Cardiol. 2018;33(4):375–376.
   PubMed Web of Science ®Google Scholar
• Smith DK, Lennon RP, Carlsgaard PB. Managing hypertension using combination therapy. Am Fam Physician. 2020;101(6):341–349.
   PubMed Web of Science ®Google Scholar
• Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res. 2017;122:1–7.
   PubMed Web of Science ®Google Scholar
• Amin S, Lux A, O’Callaghan F. The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. Br J Clin Pharmacol. 2019;85(1):37–46.
   PubMed Web of Science ®Google Scholar
• Jing Y, Wu F, Li D, et al. Metformin improves obesity-associated inflammation by altering macrophages polarization. Mol Cell Endocrinol. 2018;461:256–264.
   PubMed Web of Science ®Google Scholar
• Pascale A, Marchesi N, Govoni S, et al. The role of gut microbiota in obesity, diabetes mellitus, and effect of metformin: new insights into old diseases. Curr Opin Pharmacol. 2019;49:1–5.
   PubMed Web of Science ®Google Scholar
• Dean A, Nilsen M, Loughlin L, et al. Metformin reverses development of pulmonary hypertension via aromatase inhibition. Hypertension. 2016;68(2):446–454.
   PubMed Web of Science ®Google Scholar
• Duan Q, Song P, Ding Y, et al. Activation of AMP-activated protein kinase by metformin ablates angiotensin II-induced endoplasmic reticulum stress and hypertension in mice in vivo. Br J Pharmacol. 2017;174(13):2140–2151.
   PubMed Web of Science ®Google Scholar
• Wu K, Wei P, Liu M, et al. To reveal pharmacological targets and molecular mechanisms of curcumol against interstitial cystitis. J Adv Res. 2019;20:43–50.
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhou R, Liang X, et al. Pharmacological targets and molecular mechanisms of plumbagin to treat colorectal cancer: a systematic pharmacology study. Eur J Pharmacol. 2020;881:173227.
   PubMed Web of Science ®Google Scholar
• Zhou R, Wu K, Su M, et al. Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma. Environ Toxicol Pharmacol. 2019;70:103200.
   PubMed Web of Science ®Google Scholar
• Li R, Guo C, Li Y, et al. Therapeutic targets and signaling mechanisms of vitamin C activity against sepsis: a bioinformatics study. Brief Bioinform. 2021;22(3):bbaa079.
   PubMed Web of Science ®Google Scholar
• Li R, Guo C, Li Y, et al. Therapeutic target and molecular mechanism of vitamin C-treated pneumonia: a systematic study of network pharmacology. Food Funct. 2020;11(5):4765–4772.
   PubMed Web of Science ®Google Scholar
• Su M, Guo C, Liu M, et al. Therapeutic targets of vitamin C on liver injury and associated biological mechanisms: a study of network pharmacology. Int Immunopharmacol. 2019;66:383–387.
   PubMed Web of Science ®Google Scholar
• Li R, Wu K, Li Y, et al. Integrative pharmacological mechanism of vitamin C combined with glycyrrhizic acid against COVID-19: findings of bioinformatics analyses. Brief Bioinform. 2021;22(2):1161–1174.
   PubMed Web of Science ®Google Scholar
• Li R, Li Y, Liang X, et al. Network pharmacology and bioinformatics analyses identify intersection genes of niacin and COVID-19 as potential therapeutic targets. Brief Bioinform. 2021;22(2):1279–1290.
   PubMed Web of Science ®Google Scholar
• Li R, Wu K, Li Y, et al. Revealing the targets and mechanisms of vitamin A in the treatment of COVID-19. Aging (Albany NY). 2020;12(15):15784–15796.
   PubMedGoogle Scholar
• Nong Y, Liang Y, Liang X, et al. Pharmacological targets and mechanisms of calycosin against meningitis. Aging (Albany NY). 2020;1(19):19468–19492.
   Google Scholar
• Li J, Guo C, Lu X, et al. Anti-colorectal cancer biotargets and biological mechanisms of puerarin: study of molecular networks. Eur J Pharmacol. 2019;858:172483.
   PubMed Web of Science ®Google Scholar
• Li R, Ma X, Song Y, et al. Anti‐colorectal cancer targets of resveratrol and biological molecular mechanism: analyses of network pharmacology, human and experimental data. J Cell Biochem. 2019;120(7):11265–11273.
   PubMed Web of Science ®Google Scholar
• Li R, Song Y, Ji Z, et al. Pharmacological biotargets and the molecular mechanisms of oxyresveratrol treating colorectal cancer: network and experimental analyses. Biofactors. 2020;46(1):158–167.
   PubMed Web of Science ®Google Scholar
• Li R, Huang C, Ho JCH, et al. The use of glutathione to reduce oxidative stress status and its potential for modifying the extracellular matrix organization in cleft lip. Free Radic Biol Med. 2021;164:130–138.
   PubMed Web of Science ®Google Scholar
• Qin X, Huang C, Wu K, et al. Anti-coronavirus disease 2019 (COVID-19) targets and mechanisms of puerarin. J Cell Mol Med. 2021;25(2):677–685.
   PubMed Web of Science ®Google Scholar
• Li R, Guo C, Li Y, et al. Functional benefit and molecular mechanism of vitamin C against perfluorooctanesulfonate-associated leukemia. Chemosphere. 2021;263:128242.
   PubMed Web of Science ®Google Scholar
• Hu L, Huang X, You C, et al. Prevalence of overweight, obesity, abdominal obesity and obesity-related risk factors in southern China. PLoS One. 2017;12(9):e0183934.
   PubMed Web of Science ®Google Scholar
• Wenzel UO, Bode M, Köhl J, et al. A pathogenic role of complement in arterial hypertension and hypertensive end organ damage. Am J Physiol Heart Circ Physiol. 2017;312(3):349–354.
   Web of Science ®Google Scholar
• Anderson AJ, Andrew R, Homer NZ, et al. Metformin increases cortisol regeneration by 11βHSD1 in obese men with and without Type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101(10):3787–3793.
   PubMed Web of Science ®Google Scholar
• Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013;121:27–31.
   PubMed Web of Science ®Google Scholar
• Lee H, Lee Y, Kim J, et al. Modulation of the gut microbiota by metformin improves metabolic profiles in aged obese mice. Gut Microbes. 2018;9(2):155–165.
   PubMed Web of Science ®Google Scholar
• Lai YC, Tabima DM, Dube JJ, et al. SIRT3-AMP-Activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction. Circulation. 2016;133(8):717–731.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295.
   PubMed Web of Science ®Google Scholar
• Timper K, Denson JL, Steculorum SM, et al. Improves energy and glucose homeostasis in obesity via enhanced central IL-6 trans-Signaling. Cell Rep. 2017;19(2):267–280.
   PubMed Web of Science ®Google Scholar
• Wallenius K, Jansson JO, Wallenius V. The therapeutic potential of interleukin-6 in treating obesity. Expert Opin Biol Ther. 2003;3(7):1061–1070.
   PubMed Web of Science ®Google Scholar
• Durham GA, Palmer TM. Is there a role for prostanoid-mediated inhibition of IL-6 trans-signalling in the management of pulmonary arterial hypertension? Biochem Soc Trans. 2019;47(4):1143–1156.
   PubMedGoogle Scholar
• Pullamsetti SS, Seeger W, Savai R. Classical IL-6 signaling: a promising therapeutic target for pulmonary arterial hypertension. J Clin Invest. 2018;128(5):1720–1723.
   PubMed Web of Science ®Google Scholar
• Madrigal JL, Caso JR. The chemokine (C-C motif) ligand 2 in neuroinflammation and neurodegeneration. Adv Exp Med Biol. 2014;824:209–219.
   PubMed Web of Science ®Google Scholar
• Samaan MC, Obeid J, Nguyen T, et al. Chemokine (C-C motif) Ligand 2 is a potential biomarker of inflammation & physical fitness in obese children: a cross-sectional study. BMC Pediatr. 2013;13(1):47.
   PubMedGoogle Scholar